FDA Approves Sciele’s Sular Sustained-Release For Hypertension
This article was originally published in The Pink Sheet Daily
Executive Summary
Approval comes roughly six months ahead of patent expiration for Sular immediate-release.
You may also be interested in...
GSK Receives Approvable Letter For Once-Daily Formulation Of Requip
Extended-release version will reduce Parkinson’s disease patients’ “off time” by about two hours a day, clinical data show.
Hologic's Adiana Permanent Birth Control Device Takes On Conceptus' Essure
Adiana uses a polymer matrix insert to block the fallopian tubes instead of a metal coil, offering a benefit over Essure, which carries a perforation risk on implantation, Hologic exec says.
MADIT-CRT Data Support Expanded Cardiac Resynchronization Market
The results show that cardiac resynchronization defibrillators "slow the progression of heart failure in asymptomatic and mildly symptomatic patients," potentially expanding the market by $600 million.